我要投票 龙牡在钙片行业中的票数:213
· 外 推 电 报 ·
2025-04-27 23:09:18 星期日

【龙牡是哪个国家的品牌?】

龙牡是什么牌子?「龙牡」是武汉健民药业集团股份有限公司旗下著名品牌。该品牌发源于湖北,由创始人刘勤强在2002期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力龙牡品牌出海!通过在本页面挂载龙牡品牌的产品链接和联系方式,可以提高龙牡产品曝光!跨境电商爆单神器,目前只要100元/年哦~

龙牡壮骨颗粒是武汉健民集团旗下一个有着近20年辉煌历史、创造了中国医药界长盛不衰奇迹的知名品牌,整整抚育了中国两代儿童的健康成长。

龙牡壮骨颗粒的的主要药材(如茯苓、麦冬等)都直接选用武汉健民集团专门建设的GAP药材种植基地的原料,药材天然地道。生产过程中的每个环节、每道工序都有严格的质控标准,做到了“不合格的原料不进厂,不合格的半成品不转到下道工序,不合格的产品不出厂”。

“龙牡”的面世和畅销,创造了令人惊叹的市场业绩和品牌价值,也使得武汉健民——一个有着悠久历史、而却依然年轻的企业焕发出勃勃的生机,从此享誉长城内外,大江南北。

“龙牡”,曾经独领儿童补钙产品市场的风骚。而如今,它却受到了来自其它同类竞品的强力竞争和挑战,面临着市场份额被不断蚕食和瓜分的严峻局面。抚育了中国整整二代人的茁壮成长。

1985年在武汉市儿童医院出生,填补了我国以中药为主体,防治小儿佝偻病的空白;

1990年被收载入湖北省药品标准;

1992年被列为国家唯一的补钙一级中药保护品种;

1993年被中国儿童保护中心推荐为最佳小儿补钙、促进钙质吸收药品;

1994年被全国佝偻病防治协作组列为首推中成药;

1995年被收载入卫生部药品标准;

1999年被列为国家基本药物;

2000年被中国药典2000版收载;

2002年被列为国家处方药与非处方药(OTC)双跨品种;

同年,被《中医儿科学》(新世纪全国高等中医院校规划教材)收载。

武汉健民为中国医药工业50强企业,集团股份有限公司是国家重点高新技术企业、全国中成药小儿用药生产基地、全国重点中药企业。集团的前身是中国最古老的四大中药名店之一的叶开泰药店,距今已有近四个世纪的历史,现拥有十余个子公司,集生产、科研、经贸于一体,年生产能力近十亿元。

改革开放以来,集团公司以振兴民族医药为己任,积极推进企业改革,不断探索新的管理体制和运行机制,大力提高企业创新能力,促进了公司的全面发展,企业获得了比以往任何时候都好的社会效益和经济效益,创造了国有企业稳健经营的奇迹,综合实力跻身于全国企业500强和行业50强。近几年,集团大力实施科技兴业战略,确立了坚持以中药研发、生产和销售为主业,重点开发市场急需的小儿用药,老年用药和重大疑难病症用药,构建以中药现代化、产业化为基础,以高新技术药品为支撑的科技先导型医药集团。

目前,健民集团已成功地研制和开发出以龙牡壮骨颗粒、健民咽喉片、健脾生血颗粒、便通胶囊、慢肝宁胶囊为代表的系列产品,形成了集团蔚为壮观的"名牌林",产品行销全国,远销东南亚及欧美国家和地区。集团在近些年中相继荣获"全国质量效益型先进企业"、"全国中药行业优秀企业"、"全国五一劳动奖状"等称号,被誉为"搞好搞活国有企业的一面旗帜","健民"商标亦荣获"驰名保护"称号。一个以中药产业为基础,以高新科技为特征的健民集团必将在新的世纪里创更辉煌的业绩,谱写出振兴国药的优美乐章。

英文翻译:Longmu Zhuanggu Granule is a well-known brand under Wuhan Jianmin group, which has a glorious history of nearly 20 years and has created a long-lasting miracle in the field of Chinese medicine. It has nurtured the healthy growth of two generations of children in China. The main medicinal materials of Longmu Zhuanggu granules (such as Poria cocos, Ophiopogon japonicus, etc.) are directly selected from the gap medicinal materials planting base specially built by Wuhan Jianmin group, which are natural and authentic. There are strict quality control standards for each link and process in the production process, so that "unqualified raw materials are not allowed to enter the factory, unqualified semi-finished products are not transferred to the next process, and unqualified products are not allowed to leave the factory". The appearance and best-selling of "Longmu" has created amazing market performance and brand value, and also made Wuhan Jianmin, an enterprise with a long history but still young, full of vitality. Since then, it has been famous inside and outside the Great Wall, North and south of the river. "Longmu" once led the market of children's calcium supplement products. But now, it is faced with strong competition and challenge from other competitors, and the market share is constantly eroded and divided. He nurtured two generations of Chinese people. Born in Wuhan children's Hospital in 1985, it has filled in the blank of prevention and treatment of rickets in China with traditional Chinese medicine as the main body; in 1990, it was included in the drug standard of Hubei Province; in 1992, it was listed as the only one level of protection of traditional Chinese medicine for calcium supplement; in 1993, it was recommended as the best drug for children's calcium supplement and calcium absorption by China children's protection center; in 1994, it was recommended by the National Coordination Group for prevention and treatment of rickets It was listed as the first Chinese patent medicine; in 1995, it was listed in the drug standard of the Ministry of health; in 1999, it was listed as the national basic drug; in 2000, it was listed in the 2000 edition of the Chinese Pharmacopoeia; in 2002, it was listed as the national prescription medicine and over-the-counter medicine (OTC) double cross varieties; in the same year, it was listed in the pediatrics of traditional Chinese medicine (the textbook for the planning of the national higher education of traditional Chinese medicine in the new era). Wuhan Jianmin is one of the top 50 enterprises in China's pharmaceutical industry. The Group Co., Ltd. is a national key high-tech enterprise, a national production base of Chinese patent medicine for children and a national key Chinese medicine enterprise. The group's predecessor is Ye Kaitai drugstore, one of the four oldest famous traditional Chinese medicine stores in China. It has a history of nearly four centuries. Now it has more than ten subsidiaries, integrating production, scientific research and economic and trade, with an annual production capacity of nearly one billion yuan. Since the reform and opening up, the group company has taken the revitalization of national medicine as its own duty, actively promoted the enterprise reform, constantly explored new management system and operation mechanism, vigorously improved the innovation ability of the enterprise, promoted the overall development of the company, obtained better social and economic benefits than ever before, created a miracle of steady operation of state-owned enterprises, and its comprehensive strength ranks among Top 500 enterprises and top 50 industries in China. In recent years, the group has vigorously implemented the strategy of developing industry through science and technology, established a science and technology leading pharmaceutical group based on the modernization and industrialization of traditional Chinese medicine, supported by high-tech drugs, which adheres to the R & D, production and sales of traditional Chinese medicine as the main business, focuses on the development of children's drugs, elderly drugs and drugs for major and difficult diseases urgently needed in the market. At present, Jianmin group has successfully developed and developed a series of products represented by Longmu Zhuanggu granules, Jianmin Yanhou tablets, Jianpi Shengxue granules, Bentong capsules and manganning capsules, forming a spectacular "famous brand forest" of the group, which is sold all over the country and exported to Southeast Asia, European and American countries and regions. In recent years, the group has been awarded the titles of "national advanced quality and benefit enterprise", "national excellent enterprise in traditional Chinese medicine industry", "National May 1st Labor Award", etc., known as "a banner for invigorating state-owned enterprises", and the trademark of "invigorating the people" has also been awarded the title of "well-known protection". A Jianmin group based on traditional Chinese medicine industry and characterized by high and new technology is bound to make more brilliant achievements in the new century and compose a beautiful movement to revitalize traditional Chinese medicine.

本文链接: https://www.waitui.com/brand/ef134bbd9.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

中金公司:美图生活场景国内付费渗透率达5.2%

36氪获悉,中金公司研报透露,预计截至2月,美图公司生活场景下的国内付费渗透率已经达到5.2%。该场景下的产品包括美图秀秀、美颜相机、Wink等。据研报显示,美图生活场景产品国内付费渗透率突破5%,主要得益于生成式AI对传统功能的重新构建,如用AI去双下巴取代传统的手动推图,带来更好的用户体验和效果,促进订阅转化率提升。美图对生活场景应用订阅渗透率的长期目标为10%。

2小时前

惠誉博华:商业银行扩表节奏趋缓

36氪获悉,近日惠誉博华商业银行2024年度业绩点评。报告显示,2024年商业银行总资产同比增速回落至4.8%,结束此前连续三年的双位数扩张周期。从银行机构类型看呈现显著分化态势:城商行以8.9%的资产增速领跑,农商行以6.0%的增速紧随其后,国有大行与股份制银行分别录得3.9%和2.7%的增速。这种梯度差异映射出不同类别银行面临的经营环境——头部城商行凭借区域经济韧性维持相对活跃的资产扩张,而股份制银行负债端受制于存款成本刚性约束难以匹配国有大行资金优势,资产端受风险偏好与定价能力限制难以深度渗透区域下沉市场,导致信贷资源配置效率持续承压,近三年资产增速中枢较2019至2021年下降逾6个百分点,信贷市场正从增量竞争向存量优化转换。

2小时前

EHL酒店管理商学院将举办2025 年首届开放创新峰会

36氪获悉,EHL酒店管理商学院近日宣布,首届 EHL开放创新峰会将于5月20-21日在EHL瑞士洛桑校区举行。据悉本届峰会将围绕食品的未来、再生经济、奢品新义三个主题,打造切实可行的解决方案。EHL创新中心首席执行官Andrea Monti指出:“在这样一个充满活力与变革的时代,酒店及泛服务业对创新的需求比以往任何时候都更为迫切。”

2小时前

字节启动Top Seed大模型顶尖人才计划2026届校招

36氪获悉,4月27日,字节跳动Seed正式启动2026届Top Seed大模型顶尖人才校招计划。据了解,此前3月Top Seed开放了研究型实习生招聘,今日起正式启动2026届校招,计划招募约30位顶尖应届博士。本届Top Seed研究课题包括大语言模型、机器学习算法和系统、多模态生成、多模态理解、语音等方向,基本覆盖大模型研究各个领域。值得一提的是,本届Top Seed强调不限专业背景,更关注研究潜力,希望寻找具有极强技术信仰与热情、具备出色研究能力、富有好奇心和驱动力的年轻研究者。

2小时前

硅基智能1000万美元购入DUIX.com域名

近日,AI数字人科技公司硅基智能以1000万美元收购稀缺四字母.com域名DUIX.com,并同步上线同名数字人实时交互平台。据介绍,DUIX,全称Dialogue User Interface System,定位为新一代数字人智能交互基础设施,提供API接入、SDK开发包、免费实时体验入口及多场景应用案例。该平台支持数字人多模态交互,覆盖情感陪伴、客服、教育、医疗、游戏等应用场景,帮助开发者快速搭建实时交互式体验。

2小时前

本页详细列出关于龙牡的品牌信息,含品牌所属公司介绍,龙牡所处行业的品牌地位及优势。
咨询